BDC providers strongly recommend the COVID-19 vaccination to all people with T1D, including those who have been previously diagnosed with COVID-19.
People with T1D are prioritized to receive the vaccine in Colorado, thanks to the lobbying led by the JDRF Mountain West Chapter, CDF and BDC.
For details, please visit: jdrf.org/mountainwest/2021/02/11/t1d-covid19-vaccine-distribution-in-colorado/
If you have had a severe adverse reaction to another vaccine, or a history of anaphylaxis, talk with your health care provider prior to signing up for the vaccine.
303.724.2323
The Center provides state-of-the-art diabetes care to >7,500 active patients: 4,600 children and 2,900 adults with diabetes from the Rocky Mountain Region as well as receiving national and international referrals. We provide inpatient care to patients with any type of diabetes who are seen at the Children’s Hospital Colorado. We serve remote areas of the Rocky Mountain Region through our telemedicine program. The division also features clinical epidemiology studies including multicenter studies and trials with partners around the world.
Barbara Davis Center serves more than 90% of Colorado children diagnosed with type 1 diabetes. According to the SEARCH for Diabetes in Youth study, over the past ten years BDC provided care to 3,222 of the ~3,500 children who were diagnosed in Colorado. Completing more than 20,000 ambulatory encounters per year, BDC is the largest outpatient clinic for patients with type 1 diabetes in the U.S. and possibly the world. BDC professionals include physicians, nurses, dieticians, social workers, and a pharmacist dedicated to the special needs of pediatric and adult patients.
The Barbara Davis Center serves as a model for combining basic and clinical investigation.
The Center is a consistent incubator for novel ideas and discoveries in the immunology, genetics, and cell biology of diabetes that have developed into diagnostic assays now standard in diabetes research. The BDC research goals include investigation of the causes of type 1 diabetes, the early detection of autoimmunity, prevention and early intervention. In addition we are developing new treatments, including a focus on the artificial pancreas, and prevention strategies for complications of both type 1 and type 2 diabetes, and the outcomes of care of type 1 diabetes.
Learn more about our research by clicking the links below:
Our Mission